Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought

Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought

Source: 
Center for Biosimilars
snippet: 

Biocon Biologics and Mylan said they have launched the long-acting insulin glargine product Semglee on the US market and hope to obtain formal biosimilar status for it. Semglee was approved in June as an equivalent to Sanofi’s Lantus insulin glargine, but not as a biosimilar, owing to the regulatory pathway taken.